L-dopa and Arousal

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 1974 Apr 1

PMID 4838912

Citations 7

Authors

T B Horvath

R A Meares

Affiliations

Soon will be listed here.

Abstract

In 10 patients with Parkinsonism, treatment with L-dopa was associated with a rise in the skin conductance level and its fluctuations, an increased electromyographic activity in the frontalis muscle, and with faster reaction times. The change of skin conductance in response to a loud noise also increased and its habituation to the repetition of the stimulus was delayed. One patient developed a schizophreniform psychosis and showed high arousal and absent habituation. It is possible that dopamine is the transmitter associated with the arousal reaction and that it plays a part in the pathogenesis of schizophrenia.

Citing Articles

Dopaminergic stimulation in unilateral neglect.

Geminiani G, Bottini G, Sterzi R J Neurol Neurosurg Psychiatry. 1998; 65(3):344-7.

PMID: 9728946 PMC: 2170229. DOI: 10.1136/jnnp.65.3.344.

Usefulness of movement time in the assessment of Parkinson's disease.

Zappia M, Montesanti R, Colao R, Quattrone A J Neurol. 1994; 241(9):543-50.

PMID: 7799003 DOI: 10.1007/BF00873517.

Akinesia in Parkinsonism. Relation between spontaneous movement (other than tremor) and voluntary movements made on command.

Meyer C J Neurol Neurosurg Psychiatry. 1982; 45(7):582-5.

PMID: 7119827 PMC: 491471. DOI: 10.1136/jnnp.45.7.582.

Recognition memory in Parkinson's disease.

Flowers K, Pearce I, Pearce J J Neurol Neurosurg Psychiatry. 1984; 47(11):1174-81.

PMID: 6502175 PMC: 1028083. DOI: 10.1136/jnnp.47.11.1174.

Dopamine-sensitive alternation and collateral behaviour in a Y-maze: effects of d-amphetamine and haloperidol.

Oades R, Taghzouti K, Simon H, Le Moal M Psychopharmacology (Berl). 1985; 85(1):123-8.

PMID: 3920694 DOI: 10.1007/BF00427335.

References

Snyder S . Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry. 1972; 27(2):169-79. DOI: 10.1001/archpsyc.1972.01750260021004. View

Marsh G, Markham C, ANSEL R . Levodopa's awakening effect on patients with Parkinsonism. J Neurol Neurosurg Psychiatry. 1971; 34(3):209-18. PMC: 1083453. DOI: 10.1136/jnnp.34.3.209. View

Hornykiewicz O . Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966; 18(2):925-64. View

Meares R, Horvath T . A physiological difference between hallucinosis and schizophrenia. Br J Psychiatry. 1973; 122(571):687-8. DOI: 10.1192/bjp.122.6.687. View

Chapman J, MCGHIE A . A comparative study of disordered attention in schizophrenia. J Ment Sci. 1962; 108:487-500. DOI: 10.1192/bjp.108.455.487. View

Yahr M, Duvoisin R, Schear M, BARRETT R, HOEHN M . Treatment of parkinsonism with levodopa. Arch Neurol. 1969; 21(4):343-54. DOI: 10.1001/archneur.1969.00480160015001. View

Schildkraut J . The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965; 122(5):509-22. DOI: 10.1176/ajp.122.5.509. View

WARBURTON J . Memory disturbance and the Parkinson syndrome. Br J Med Psychol. 1967; 40(2):169-71. DOI: 10.1111/j.2044-8341.1967.tb00566.x. View

Ungerstedt U . Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand Suppl. 1971; 367:1-48. DOI: 10.1111/j.1365-201x.1971.tb10998.x. View

10.

Lindsley D . Psychological phenomena and the electroencephalogram. Electroencephalogr Clin Neurophysiol. 1952; 4(4):443-56. DOI: 10.1016/0013-4694(52)90075-8. View

11.

Knopp W . Psychiatric changes in patients treated with levodopa. I. The clinical experiment. Neurology. 1970; 20(12):Suppl:23-30. View

12.

Jouvet M . Neurophysiology of the states of sleep. Physiol Rev. 1967; 47(2):117-77. DOI: 10.1152/physrev.1967.47.2.117. View

13.

Lammers A, van Rossum J . Bizarre social behaviour in rats induced by a combination of a peripheral decarboxylase inhibitor and DOPA. Eur J Pharmacol. 1968; 5(1):103-6. DOI: 10.1016/0014-2999(68)90163-5. View

14.

Bunney W, Janowsky D, Goodwin F, Davis J, Brodie H, Murphy D . Effect of L-DOPA on depression. Lancet. 1969; 1(7600):885-6. DOI: 10.1016/s0140-6736(69)91921-7. View

15.

Barbeau A . Long-term side-effects of levodopa. Lancet. 1971; 1(7695):395. DOI: 10.1016/s0140-6736(71)92226-4. View

16.

SCHECKEL C, Boff E, Pazery L . Hyperactive states related to the metabolism of norepinephrine and similar biochemicals. Ann N Y Acad Sci. 1969; 159(3):939-58. DOI: 10.1111/j.1749-6632.1969.tb12990.x. View

17.

Butcher L, Engel J . Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition. Brain Res. 1969; 15(1):233-42. DOI: 10.1016/0006-8993(69)90322-9. View

18.

COTZIAS G, PAPAVASILIOU P, GELLENE R . Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969; 280(7):337-45. DOI: 10.1056/NEJM196902132800701. View

19.

CELESIA G, Barr A . Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol. 1970; 23(3):193-200. DOI: 10.1001/archneur.1970.00480270003001. View

20.

Bunney Jr W, Brodie H, Murphy D, Goodwin F . Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry. 1971; 127(7):872-81. DOI: 10.1176/ajp.127.7.872. View